Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

Springer Science and Business Media LLC - Tập 12 Số 1 - 2022
Mayssa El Raziky1,2, Sherif Hamdy1,2, Yasser Hamada2, Nermin Mohamed Abdelaziz3, Mohamed Hassany4, Wahid Doss2, Zeinab Zakaria2
1Cairo Fatemic Hospital, Cairo, Egypt
2Department of Endemic Medicine and Hepato-Gastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt
3El Sahel Teaching Hospital, Cairo, Egypt
4National Hepatology and Tropical Medicine Research Institute, NHTMRI, Cairo, Egypt

Tóm tắt

Abstract Background This study aimed to evaluate the efficacy, safety and tolerability of SOF/DCV ± RBV in a cohort of Egyptian patients with chronic hepatitis C (CHC)-induced cirrhosis with decompensation (class B7–B9). Results After excluding the 9 patients who withdrew, SVR12 rate according to per protocol analysis was 82.9% (92/111), non-response and relapse rates were 2.7% (3/111) for each, 4 patients died secondary to hematemesis, and 8.1% stopped therapy due to worsening of Child’s class. SVR12 rate was significantly higher among patients with higher baseline WBCs count and lower among patients with Child-Pugh class B9. All treatment intolerant patients had ascites in pre-treatment assessment (P = 0.02). There was a significant decline in the levels of hemoglobin, ALT and AST, and serum bilirubin (P < 0.001) and a significant increase in albumin level (P < 0.001) at the end of treatment when compared to their pre-treatment levels. Follow-up of the three HCC did not show evidence of tumor recurrence. Conclusions The SOF/DCV combination ± ribavirin is an effective and safe regimen for patients with CHC induced cirrhosis with mild decompensation. Treatment did not increase the risk of HCC recurrence.

Từ khóa


Tài liệu tham khảo

Dore GJ, Ward J, Thursz M (2014) Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat 21(s1):1–4

Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S (2013) The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther 38(9):1065–1075

Zopf S, Kremer AE, Neurath MF, Siebler J (2016) Advances in hepatitis C therapy: What is the current state-what come’s next? World J Hepatol 8(3):139

American Association for the Study of Liver Diseases & Infectious Diseases society of America (2014). Recommendation for testing , managing , and treating hepatitis C.

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878–1887

Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y et al (2013) Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58(4):646–654

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR et al (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373(8):714–725

Estrabaud E, Vidaud M, Marcellin P, Asselah T (2012) Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 57:1110–1125

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 61:77–87

El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K et al (2017) National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat 24(4):262–267

Sharma S, Khalili K, Nguyen GC (2014) Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 20(45):16820

Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H et al (2018) Generic daclatasvir plussofosbuvir, with or without ribavirin, in treatment of chronichepatitis C: real-world results from 18 378 patients inEgypt. Aliment Pharmacol Ther 47(3):421–431

El-Khayat H, Fouad Y, Mohamed HI, El-Amin H, Kamal EM, Maher M, Risk A (2018) Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther 47(5):674–679

Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M et al (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581–585

Fernández Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J et al (2017) Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology 65(6):1810–1822

Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F et al (2016) Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol 14(12):1821–1830

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A et al (2018) Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents. Gastroenterology 155(2):411–421.e4

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M et al (2017) Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 67(6):1204–1212

Bang CS, Song IH (2017) Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 17(1):46

Reig M, Boix L, Bruix J (2017) The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver Int 37(S1):136–139

Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P, Coelho R (2016) High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 65(5):1070–1071

Carrier P, Essig M, Debette-Gratien M, Sautereau D, Rousseau A, Marquet P, Loustaud-Ratti V (2016) Anti-hepatitis C virus drugs and kidney. World J Hepatol 8(32):1343

Abd El Rahman MM, Galal GM, Abd El Hamid RM, Abd Allah SK (2020) Efficacy, safety, and biochemical response of sofosbuvir and daclatasvir combination in chronic hepatitis C treated patients in Sohag Governorate. Sohag Med J Effi, Saf Biochem Resp Sofosbuvir 24(1):104–111

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 12 Số 1

Thông tin tác giả